Terms: = Prostate cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Clinical Outcome
4 results:
1. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
[TBL] [Abstract] [Full Text] [Related]
2. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients.
Alix-Panabières C
Recent Results Cancer Res; 2012; 195():69-76. PubMed ID: 22527495
[TBL] [Abstract] [Full Text] [Related]
3. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
Jhavar S; Brewer D; Edwards S; Kote-Jarai Z; Attard G; Clark J; Flohr P; Christmas T; Thompson A; Parker M; Shepherd C; Stenman UH; Marchbank T; Playford RJ; Woodhouse C; Ogden C; Fisher C; Kovacs G; Corbishley C; Jameson C; Norman A; De-Bono J; Bjartell A; Eeles R; Cooper CS
BJU Int; 2009 May; 103(9):1256-69. PubMed ID: 19040532
[TBL] [Abstract] [Full Text] [Related]
4. Influence of muc1 genetic variation on prostate cancer risk and survival.
Strawbridge RJ; Nister M; Brismar K; Li C; Lindström S
Eur J Hum Genet; 2008 Dec; 16(12):1521-5. PubMed ID: 18628787
[TBL] [Abstract] [Full Text] [Related]
